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D
iabetic kidney disease (DKD) is the most severe diabetes complication because it is associated with progression to end-stage kidney disease (ESKD) and carries a high risk of premature death. DKD is characterized by progressive proteinuria and interstitial fibrosis, resulting in a decline in kidney function. Proteinuria is one of the most important prognostic risk factors for kidney disease progression. Defects in the glomerular filtration barrier, as manifested by proteinuria, are a principal pathological feature of DKD. Podocytes are the visceral epithelial cells that reside on the glomerular basement membrane (GBM) outside glomerular capillaries, and they are anchored to the GBM through integrin complexes that are present in the soles of podocyte foot processes. The molecular mechanisms underlying the loss of podocyte permselectivity in DKD are under intense investigation (1, 2) .
Angiopoietin-like protein 2 (ANGPTL2), a proinflammatory circulating protein, is produced by endothelial cells, adipocytes, and macrophages (3) . The expression and secretion of ANGPTL2 are significantly increased in cells stressed by pathological stimuli such as obesity, diabetes, or metabolic syndrome. Excess ANGPTL2 signaling is proinflammatory in pathological states and contributes to the development of diabetes complications. Morinaga et al. (4) demonstrated that genetic depletion of angptl2 confers amelioration of mouse kidney fibrosis induced by unilateral ureteral obstruction, implying that ANGPTL2, predominantly in renal tubular compartments, activates TGF-b signaling. Furthermore, recent clinical studies have indicated that circulating levels of ANGPTL2 are significantly elevated in various chronic inflammatory diseases, including diabetes. These reports indicate that ANGPTL2 levels are more than an inflammatory biomarker and may contribute to the pathogenesis of kidney injury.
Because epigenetic markers are modified in response to environmental changes (5), we hypothesized that signals from diabetes or kidney dysfunction induce epigenetic changes to the angptl2 gene, thereby increasing its expression. In this study, to clarify the molecular linkage between the abnormal production of ANGPTL2 and progression of DKD, we analyzed the relationship between serum levels of ANGPTL2 and the decline of kidney function by using a cross-sectional study and retrospective cohort and investigated the molecular mechanisms of ANGPTL2 synthesis and ANGPTL2-induced podocyte injury.
Materials and Methods

Study sample
We performed two observational studies, a cross-sectional study and a retrospective cohort study. The cross-sectional study included a population undergoing medical checkup. In the cohort study, we collected all patient data and clinical courses by using patient records from the Department of Endocrinology and Nephrology in the University of Yamanashi Hospital from 2005 to 2007. One hundred fifty-five patients were included to elucidate the association between the progression of podocyte injury and ANGPTL2 in patients with diabetes. They were followed up for a median of 7 years (25%, 5 years; 75%, 9 years) in accordance with previous reports (6, 7) . Two patients with cellulitis and bacteremia were excluded, because their HbA1c and body mass index (BMI) were radically changed from their baseline. Eight patients who stopped their visits and from whom data could not be collected were excluded. Baseline data on medication and diabetes complications were registered with the use of a standardized questionnaire, which was completed by the attending physician using an information form and hospital records. The primary end points were progression of DKD stages, which are defined as declines from normoalbuminuria to microalbuminuria or macroalbuminuria, from microalbuminuria to macroalbuminuria, and from macroalbuminuria to ESKD. The study protocol was approved by the ethics committees of the University of Yamanashi and Isawa Onsen Hospital in accordance with the Declaration of Helsinki. Written informed consent was obtained from each patient. (8) . Urine albumin excretion was quantified from qualitative urine data in the cross-sectional study. In the cohort study, urine creatinine (Cr) and albumin were measured with the turbidimetric immunoassay method. The albumin/ creatinine ratio (ACR) was calculated by dividing urine albumin by urine Cr concentration. ANGPTL2 concentration was measured with a human ANGPTL2 ELISA (Immuno-Biological Laboratories, Fujioka, Japan). Insulin concentration was measured with a Mercodia insulin ELISA kit (Mercodia AB, Uppsala, Sweden). Stages of DKD were defined based on the ACR in at least two urine collections. Patients were divided by ACR categorically into those with normal ACR (,30 mg/g Cr), microalbuminuria (30 to 300 mg/g Cr), and macroalbuminuria (.300 mg/g Cr). During follow-up periods, all patients were managed by their own practitioner and diabetes care team, without any attempt to standardize treatment.
Cell culture
Conditionally immortalized mouse podocytes, kindly provided by Dr. Katuhiko Asanuma's laboratory (Chiba University, Japan) with permission from Dr. Peter Mundel (Mt. Sinai School of Medicine, New York, NY), were cultured as described in previous reports (9, 10) .
Monocytes were separated from peripheral blood by density gradient centrifugation with LSM™ separation medium (MP Biomedicals, Santa Ana, CA). Monocytes were cultured in macrophage serum-free media (Life Technologies, Grand Island, NY) supplemented with 25 mM HEPES, 13 Nutridoma (Roche, Basel, Switzerland), and 50 ng/mL of macrophage colony stimulating factor at a density of 1 3 10 5 cells/mL in collagen-coated dishes (Asahi Glass Co. Ltd., Shizuoka, Japan). Twenty-four hours later, 10 mM of 5-aza-2'-deoxycytidine (5-azadC) (Sigma, St. Louis, MO) was added to the media. Cells were maintained at 37°C and 5% CO 2 and left undisturbed for 3 days to promote cell adherence. Fresh media was added on day 3 after plating, and a half-media exchange was performed on day 5. Seven days after plating, cells were treated with TRIzol reagent for RNA extraction or harvested for genomic DNA extraction.
Bisulfite DNA sequencing
Genomic DNA samples were treated with bisulfite with an EpiTect® Fast Bisulfite conversion kit (Qiagen, Venlo, the Netherlands) and then were used as a template for PCR amplification of the region. Primer pairs were designed with the MethPrimer program (Li Lab, Peking Union Medical College Hospital, Beijing, China). PCR products were purified and cloned into pCR2.1-TOPO (Thermo Fisher Scientific, Waltham, MA). Individual clones were sequenced and aligned with a reference sequence with the QUMA program (RIKEN, Kobe, Japan).
Chromatin immunoprecipitation assay
The protocol for the chromatin immunoprecipitation (ChIP) assay was previously described (11) . In brief, the primer sequences used for RT-PCR were forward 5 0 -CCAGTGCCA-TCCTCTCCTTTC-3 0 and reverse 5 0 -GCTTAGGACTCTGGAG-ATG-3 0 , which correspond to the nucleotides flanking the FOXO1 binding site in the angptl2 promoter (Fig. 1A) .
Western blot analysis and immunocytochemistry
The protocols for Western blot analysis and immunocytochemistry analysis were previously described (11) . The primary antibodies used for Western blot analysis were as follows: antiphosphorylated focal adhesion kinase (FAK), antitotal FAK, and antiactinin (Cell Signaling Biotechnologies, Danvers, MA). Anti-ZO-1 antibody was purchased from Thermo Fisher Scientific.
Albumin permeability assay
For the albumin permeability assay, differentiated podocytes (5 3 10 5 cells per well) were plated on type I collagen-coated 24-well transwell plates (Corning, New York, NY) and were deprived of serum overnight when confluent. Cells were then treated with recombinant ANGPTL2, anti-integrin ab, or FAK inhibitor for 24 hours. The upper chamber was replaced with 0.25 mL RPMI 1640 and the lower chamber with 0.5 mL RPMI 1640 supplemented with 40 mg/mL BSA, and the cells were incubated for another 2 hours at 37°C. Total protein concentration in the upper compartment was determined with a BCA protein assay kit (Thermo Fisher).
Statistical analysis
Normally distributed variables are presented as mean 6 SD; otherwise, the median and interquartile ranges are presented. Highly skewed variables (e.g., duration, albuminuria, and ANGPTL2) were transformed with the natural logarithm function before use in models (ln-duration, ln-albuminuria, lnAngptl2). Intergroup comparisons were performed with the x 2 test, t test, Mann-Whitney U test, one-way ANOVA, and Kruskal-Wallis test as appropriate. The subjects were classified into two groups based on the median methylation levels, and comparisons of the characteristics between the two groups were examined.
Multivariate logistic regression models were used to analyze the values of ANGPTL2 as an explanatory variable for the progression of albumin urine stages. The relationship between the progression of DKD and baseline characteristics was Human monocytes were treated with 5-azadC or insulin and were subjected to the anti-FOXO1 antibody used for immunoprecipitation of the chromatin. Relative quantification to input is represented in the lower panel. All data are expressed as the mean 6 SD (error bars). *Bonferroni-adjusted P , 0.05. (E) Effect of a PI3 kinase inhibitor on insulin-mediated suppression of angptl2 expression. Monocytes were treated with 5-azadC, insulin, or LY29400 and subjected to quantitative real-time RT-PCR with 50 ng of cDNA in triplicate. Relative quantification of target cDNA was determined by arbitrarily setting the control value from vehicle-treated samples to 1. All data are expressed as the mean 6 SD (error bars). *Bonferroni-adjusted P , 0.05. examined with univariate logistic regression models. Sex, age, and the variables that were statistically significant in the univariate logistic regression models were included in the multivariate regression models. Area under the receiver operating characteristic (ROC) curve and cutoff values were calculated for changes of ACR to detect changes in albuminuria stage.
Comparisons of Angptl2 mRNA expression, signal intensities, or albumin permeabilities were performed by ANOVA and corrected by the Bonferroni adjustment. Statistical significance was defined as P , 0.05. All data analysis was performed with Stata 14.2 (Stata Corp. LLC, College Station, TX).
Results
We measured serum ANGPTL2 concentrations in 220 medical checkup examinees in Kua-hause Isawa, Isawa Onsen Hospital, Japan. The medians and frequencies of potential risk factors according to the tertile of serum ANGPTL2 levels are listed in Table 1 . The serum ANGPTL2 levels were significantly different between the tertile groups (Supplemental Fig. 1 ). Waist circumference, BMI, homeostatic model assessment for insulin resistance, triglycerides, diabetes duration, and Fib-4 index (a marker for liver fibrosis) were significantly higher in the upper tertile of ANGPTL2 levels. Subjects in the upper tertile of ANGPTL2 levels were likely to have lower high-density lipoprotein cholesterol and eGFR. The upper tertile had no association with sex, age, current status of albuminuria, or low-density lipoprotein cholesterol. These results are consistent with a previous report (12) and indicate that elevated serum ANGPTL2 is associated with obesity, systemic insulin resistance, fatty changes in the liver, and kidney function.
Two putative insulin response elements (IREs) in the area around the CpG island of the Angptl2 promoter (Fig. 1A) suggest that insulin signaling and DNA methylation may regulate the expression of Angptl2. To explore the effects of epigenetic changes in the Angptl2 promoter on its mRNA expression in monocytes, we determined the methylation status of the Angptl2 promoter region in circulating monocytes isolated from patients with diabetes, because they are easily accessible biomaterials and probably influenced by the body. We randomly selected 50 subjects with diabetes and DKD (eGFR median, 55.5; 25%, 20; and 75%, 77) ( Table 2 ) and conducted bisulfate sequencing analysis of the two CpGs in the promoter region of Angptl2. We found that the methylation levels of bisulfate sequence (BSF) 1 (BSF1: 2380 to 2100) and 2 (BSF2: 2125 to 79) were median 67.2% and 60.4%, respectively. The subjects were classified into two groups based on the median methylation levels of BSF1 and BSF2 [BSF1 high methylation (.67.2%) and BSF1 low methylation (,67.2%); BSF2 high methylation (.60.4%) and BSF2 low methylation (,60.4%)]. The correlation of methylation levels of BSF1 or BSF2 and serum ANGPTL2 levels are presented in Supplemental Fig. 2 . In both promoter sites, serum ANGPTL2 levels were higher in subjects with low DNA methylation compared with those with high DNA methylation ( Table 2 ; Fig. 1B and 1C ). No differences in sex, age, BMI, HbA1c, or eGFR were observed between low and high groups ( Table 2) . Values are the mean 6 SD (upper) and median (25th, 75th percentile) (lower).
Abbreviation: T, tertile. a P , 0.05.
To decipher the molecular linkage between ANGPTL2 production and the insulin signaling pathway, we determined the binding of FOXO1 (13), a key transcription factor of insulin action, to the IRE sites in the Angptl2 promoter ( Fig. 1) by ChIP assay. In cultured monocytes isolated from patients, FOXO1 binding to IREs was scarcely observed under basal conditions (Fig. 1C) . Treatment with 5-azadC, an inhibitor of DNA methylation, substantially induced FOXO1 binding to the Angptl2 promoter, whereas treatment with insulin significantly reduced the 5-azadC-mediated increase in FOXO1 binding. Consistent with these results, insulin suppressed the 5-azadC-induced mRNA expression of Angptl2 (Fig. 1D) . A PI3 kinase inhibitor, LY294002, abolished the insulin-mediated reduction in Angptl2 expression, suggesting that the insulin-PI3 kinase signaling cascade plays a suppressive role in the transcriptional activation of the Angptl2 promoter through IREs.
We next examined the relationship between serum ANGPTL2 levels and risk factors in the progression of albuminuria in patients with diabetes. The median follow-up duration was 7.1 years (95% CI, 6.6 to 7.1). One hundred forty-five patients with diabetes were divided into three groups based on their baseline characteristics (Table 3) : 82 with normoalbuminuria, 37 with microalbuminuria, and 26 with macroalbuminuria. During the observation period, 23/82 patients with normoalbuminuria progressed to microalbuminuria or macroalbuminuria, 14/37 patients with microalbuminuria progressed to macroalbuminuria, and 16/26 patients with macroalbuminuria progressed to renal death. We used the data that were collected at enrollment as the baseline. DACR and DeGFR indicate the changes in ACR and eGFR during observation periods, respectively. Univariate analyses in all subjects showed that the progression of DKD was correlated with diabetes duration, Hb, eGFR, DACR, DeGFR, and ANGPTL2. Multivariate logistic regression analyses indicated that diabetes duration and ANGPTL2 are independent risk factors for the progression of DKD (Table 4 ). ROC curves revealed that 202 mg/g Cr of DACR was the cutoff point for predicting the progression of albuminuria stages (area under the ROC curve 0.87, sensitivity 0.47, specificity 0.98). Twenty-six patients demonstrated increases in ACR of .202 mg/g Cr. Univariate analyses showed that an increase in ACR of .202 mg/g Cr was correlated with age, Hb, eGFR, diabetes duration, and ANGPTL2 (Supplemental Table 1 ). Multivariate logistic analyses indicated that eGFR, diabetes duration, and ANGPTL2 are independent risk Values are the mean 6 SD (upper) and median (25th, 75th percentile) (lower). a P , 0.05. Values are the mean 6 SD (upper) and median (25th, 75th percentile) (lower).
factors for the increases of albuminuria. These findings suggest that high levels of serum ANGPTL2 could be associated with the development of microalbuminuria, the progression to macroalbuminuria, or a decline in kidney function among patients with diabetes.
To investigate the direct effect of ANGPTL2 on podocyte function, albumin permeability across differentiated podocyte monolayers was measured in the presence or absence of ANGPTL2 in vitro. As shown in Fig. 2A, 0.3 and 1 .0 mg/mL of recombinant ANGPTL2 significantly increased albumin permeability through integrin a 5 b 1 , a putative receptor for ANGPTL2 action, as evidenced by the blockade of the ANGPTL2 effect by neutralizing antibodies against integrin a 5 b 1 . Confocal microscopy revealed linear membrane localization of zonula occludens-1 (ZO-1), a tight junctionassociated protein, in cultured podocytes under basal conditions (Fig. 2B, panel a) , and ANGPTL2 induced translocation of ZO-1 to cytosol (Fig. 2B, panel  b) (Supplemental Fig. 3) . However, the total amount of ZO-1 protein was not affected by ANGPTL2 treatment (Fig. 2C) .
The activation of FAK in podocytes induces focal adhesion rearrangement, resulting in the retraction and effacement of foot processes (15) . Treatment with ANGPTL2 remarkably increased the phosphorylation of FAK through integrin a 1 b 5 in cultured podocytes (Fig. 2D) . Moreover, a FAK inhibitor, PF228, reduced the ANGPTL2-induced albumin permeability across the cultured podocytes (Fig. 2E) . These findings strongly suggest that ANGPTL2 directly regulates glomerular permselectivity via the integrin/FAK pathway.
Discussion
In this study, we showed that serum ANGPTL2 levels were increased by obesity and insulin resistance and that DNA demethylation levels of the ANGPTL2 promoter in circulating monocytes were correlated with serum ANGPTL2 levels. In vitro, we demonstrated that ANGPTL2 induced phosphorylation of FAK via integrin a 5 b 1 and subsequently increased albumin permeability across podocytes through the translocation of ZO-1. Our present findings strongly suggest that ANGPTL2 directly regulates podocyte function and contributes to the development and progression of albuminuria in patients with diabetes.
Recent histological findings indicate that ANGPTL2 is abundantly expressed in endothelial cells and macrophages infiltrating atheromatous plaques in patients with cardiovascular disease (16) . Endothelial cell-derived ANGPTL2 accelerates vascular inflammation by activating proinflammatory signaling in endothelial cells and increasing macrophage infiltration, leading to endothelial dysfunction and atherosclerosis progression (16) . ANGPTL2 is also expressed in adipose tissue and macrophages and is closely related to adiposity and inflammation (3). Under inflammatory conditions, monocytes infiltrate adipose tissues and are polarized to the classically activated type (M1) macrophages that increase the production of proinflammatory cytokines, resulting in chronic inflammation and insulin resistance (17) . ANGPTL2 promotes adipose tissue or vascular inflammation as gauged by the accumulation and activation of macrophages and T lymphocytes, leading to systemic insulin resistance (18) . Adipose tissue-specific Angptl2 transgenic mice also develop local inflammation and subsequent endothelial dysfunction, as evidenced by increased inflammatory cytokine expression, leukocyte attachment, and macrophage infiltration in the walls of postcapillary venules within adipose tissue (3). Unilateral ureteral obstruction induces a progressive renal fibrosis similar to that seen in most human kidney disease (19) . Unilateral ureteral obstruction-induced expression of proinflammatory cytokines, macrophage infiltration, and kidney interstitial fibrosis are inhibited in angptl2 knockout mice, suggesting that ANGPTL2 evokes kidney damage through inflammation (20) . Obesity, hypoxia, and endoplasmic reticulum stress coordinately increase both the expression of angptl2 and serum levels of ANGPTL2 (12, 21) . These results suggest that elevated levels of ANGPTL2 could activate the inflammation pathway in endothelial cells, following vascular permeability and macrophage activation in the kidneys of patients with diabetes. In mammalian cells, environmental stimuli induce epigenetic changes such as DNA methylation, which is found predominantly in cytosines preceding a guanine, called CpG dinucleotides. Gene expression of angptl2 has been shown to be regulated by epigenetic modifications (14) . To explore the epigenetic regulation of angptl2 expression in patients with diabetes, we analyzed the epigenetic modulation of genomic DNA isolated from patients' monocytes, because they are easily accessible materials and they are potentially affected by the body environment. As shown in Fig. 1 , demethylation of the angptl2 promoter is correlated with serum ANGPTL2 levels in patients with diabetes who had similar baseline levels of BMI and HbA1c. The cross-sectional study indicated that elevated serum ANGPTL2 is associated with obesity and insulin resistance (Table 1) . However, demethylation of angptl2 in monocytes was independently regulated by current status of obesity or blood glucose levels ( Table 2 ). This discrepancy suggests that epigenetic modifications could occur by prolonged stimulation by obesity or blood glucose levels in vascular endothelial cells or adipose tissues and that they could coordinately contribute to the elevation of serum ANGPTL2 levels.
This study has some limitations that need to be addressed in future studies. We performed multiple logistic regression models to analyze the baseline of ANGPTL2 as an explanatory variable for the progression of DKD. This limitation exists for the retrospective cohort, which depended only on the baseline characteristics. Our study did not include the variables of blood pressure or treatment of hypertension. Another limitation is that the sample population was too small to determine whether serum ANGPTL2 could be a useful predictor of the decline in kidney function among patients with diabetes. Additional analyses together with validation studies will extend this work and provide a basis for clinical applications. DKD is characterized by elevated urinary albumin excretion, and it often progresses to macroalbuminuria, one of the most important prognostic risk factors for the progression of kidney dysfunction (22) . Glomerular visceral epithelial cells and podocytes play a critical role in maintaining the structure and function of the glomerular filtration barrier. A tight junction-associated protein, ZO-1, anchors slit diaphragm proteins to the actin cytoskeleton in podocytes through its PSD-95/disc large/ZO-1 domains (23), and it is translocated from the cell membrane to the cytosol in response to high glucose exposure, which subsequently increases albumin permeability (24) . Rincon-Choles et al. (2) also demonstrated the translocation of ZO-1 from the membrane to the cytosol in diabetes animal models. Our result demonstrates that ANGPTL2 increases albumin permeability in podocytes through the ZO-1 translocation, which is mediated by the phosphorylation of FAK. This clinical study suggests that the elevation of serum ANGPTL2 is associated with the decline in kidney function. Taken together, our present findings indicate that ANGPTL2 might be directly involved in podocyte dysfunction and independently associated with the progression of DKD stages.
In conclusion, the expression of angptl2 is regulated by epigenetic changes in DNA independent of obesity and blood glucose levels in patients with diabetes. We also demonstrated that ANGPTL2 directly induced podocyte dysfunction associated with the increase in albumin permeability. Understanding the mechanisms by which ANGPTL2 induces podocyte dysfunction will provide insights into the development of therapeutic strategies for DKD.
